INVESTIGATING THE ROLE OF KLUYVEROMYCES LACTIS IN INFLAMMATORY BOWEL DISEASE

Abstract

While many therapies for inflammatory bowel disease (IBD) were discovered over the last several years, many individuals do not respond well to the treatment, resulting in persistent symptoms and higher risk of gastrointestinal tumors. This, along with the rising incidence of IBD, underscores the need for new therapy approaches. Recent research has demonstrated important role of the gut microbiome in IBD progression, with certain microorganisms worsening the disease while others alleviate symptoms. The impact of the yeast Kluyveromyces lactis (K. lactis) on IBD remains unexplored. However, K. lactis is a common component of the human diet, often found in dairy products, and has shown probiotic potential. If this yeast exhibits anti-inflammatory properties in IBD murine models, it could lead to the development of a novel, easily administered oral treatment. Such therapy would remain in the gut for an extended period, reducing the reliance on continuous medication. The aim of the project is to asses anti-inflammatory role of yeast Kluyveromyces lactis in the treatment of inflammatory bowel disease.